SAN FRANCISCO, Sept. 27 /PRNewswire/ -- Burrill & Company announced today their investment in Sciona, Inc. (http://www.sciona.com/). Sciona is the leading company in the field of consumer-oriented genetic diagnostics. Based on the latest scientific research, Sciona has created a genetic diagnostic panel that enables manufacturers to customize personal care and nutrition products based on a person's genetic makeup. Sciona is currently located in Cambridge, UK, but plans to relocate to New Haven, Connecticut, to be nearer to strategic partner and equity stakeholder, Genaissance, Inc.
"We are very impressed with Sciona's leadership position in the field of consumer-oriented genetic diagnostics. Their CellF diagnostic panel represents the first large scale entry into the field of nutragenomics. We are confident that with Sciona's research partnerships and their continued efforts to develop new diagnostics, that they will remain in the lead of this exciting, new area of health and wellness," commented G. Steven Burrill, CEO of Burrill & Company, a San Francisco-based life sciences merchant bank.
Burrill's Nutraceuticals Capital Fund, LP and their Life Sciences Capital Fund, LP, invested $1.7 Million in a $6 Million Series C Round. The round was co-led by Burrill and Prelude Ventures, of Cambridge, UK. Other investors in the round included BASF Ventures, Semola Limited, and DSM Ventures.
About Sciona, Inc.
Sciona, Inc. is a privately held genetics company that develops tools and services which enable companies to customize personal care and nutrition products based upon an individual's genetic profile. The Company has growing revenues from its first product, introduced to the market in 2002. To date, over 4,500 consumers in the U.S. and Europe have purchased genetically personalized products or services from channel partners that utilize Sciona's technology and services. As a result, Sciona is established as the number one provider of nutritional genetic personalization and the Company's strategy is to extend this position to other segments of consumer Genetic Personalization. For more information on Sciona, please visit the company's Web site at http://www.sciona.com/.
About Burrill & Company
Burrill & Company is a life sciences merchant bank, focused exclusively on companies involved in biotechnology, pharmaceuticals, diagnostics, human healthcare and related medical technologies, wellness and Nutraceuticals, agricultural technologies, and industrial biotechnology (biomaterials/bioprocesses).
The Burrill family of venture capital funds, with over $500 million under management, includes the Burrill Life Sciences Capital Fund, the Burrill Biotechnology Capital Fund, the Burrill Agbio Capital Fund and its successor-the Burrill Agbio Capital Fund II, and the Burrill Nutraceuticals Capital Fund.
Burrill & Company assists life science companies in identifying, negotiating and closing strategic partnerships between large and small companies in providing access to resources, technologies or collaborations essential for executing their business plans.
Burrill & Company also works with major life science companies to spinout internal assets and capitalizes on their value, ranging from the outright sale s of products or businesses to creation of new companies to exploit these assets. Burrill uses its extensive network to help companies identify, assess and capture ("spin-in") products and companies strategic to building their businesses.
We have completed more than 25 strategic partnerships with a value in excess of $1.5 billion.
Strategic Advisory Services
Burrill & Company works with leaders of life science companies of all sizes (from start-up to big Pharma) on growth strategy with a focus on how strategic transactions and partnerships can enable and accelerate the achievement of corporate objectives. We combine our scientific, business operations, financial and technical skill sets with an objective advisory approach. We then work with our external clients to implement these plans, whether it is to succeed through an M&A/partnering transaction or a financing, divestiture or a restructuring.
Biotech 2004/Burrill Datacenter
Burrill & Company's annual analysis of the "State of the Industry" has been an important part of the biotech industry's view of itself over the last 18 years. Biotech 2004-Life Sciences: Back on Track, is a perspective on where the industry has been and is going and was released Q1 04. In addition, the newly created Burrill Datacenter is an online resource for keeping up-to-date information from the biotech industry at your fingertips, including updated data from Biotech 2004. To order Biotech 2004 or to subscribe to the Burrill Datacenter, visit http://www.burrilldatacenter.com/ or call 415-591-5400.
About Prelude Trust
Prelude Trust plc ("Prelude") is an investment trust, launched in 1997, with the unique objective to seek significant capital appreciation over the long term primarily through venture capital investment in unquoted high-growth technology and life science based businesses.
BASF Venture Capital Gmbh
BASF Venture Capital GmbH was established in 2001 as a wholly owned subsidiary of BASF Future Business GmbH, Ludwigshafen, Germany, and participates in startup companies by providing venture capital to open up new growth potentials. In doing so, it focuses on companies with innovative business models and technologies in which chemistry is an important key to success. Investment is channeled toward companies that can demonstrate successful applications for their product developments as well as market demand. BASF also supports these companies with its expertise.
DSM Venturing, part of the DSM Venturing & Business Development business group, is an active investor in several Venture Capital Funds and start-up companies in DSM's strategic growth fields: Food Ingredients, Pharmaceutical Intermediates and Performance Materials.
Burrill & Company